- Home
- MNPR vs DOMH Comparison
MNPR vs DOMH Comparison
Compare MNPR & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- DOMH
- Stock Information
- Founded
- MNPR 2014
- DOMH 1967
- Country
- MNPR United States
- DOMH United States
- Employees
- MNPR N/A
- DOMH N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- DOMH Biotechnology: Pharmaceutical Preparations
- Sector
- MNPR Health Care
- DOMH Health Care
- Exchange
- MNPR Nasdaq
- DOMH Nasdaq
- Market Cap
- MNPR 9.7M
- DOMH 12.1M
- IPO Year
- MNPR 2019
- DOMH N/A
- Fundamental
- Price
- MNPR $5.71
- DOMH $1.88
- Analyst Decision
- MNPR Strong Buy
- DOMH
- Analyst Count
- MNPR 3
- DOMH 0
- Target Price
- MNPR $22.00
- DOMH N/A
- AVG Volume (30 Days)
- MNPR 333.7K
- DOMH 15.4K
- Earning Date
- MNPR 11-07-2024
- DOMH 11-04-2024
- Dividend Yield
- MNPR N/A
- DOMH N/A
- EPS Growth
- MNPR N/A
- DOMH N/A
- EPS
- MNPR N/A
- DOMH N/A
- Revenue
- MNPR N/A
- DOMH $9,509,000.00
- Revenue This Year
- MNPR N/A
- DOMH N/A
- Revenue Next Year
- MNPR N/A
- DOMH N/A
- P/E Ratio
- MNPR N/A
- DOMH N/A
- Revenue Growth
- MNPR N/A
- DOMH 13292.96
- 52 Week Low
- MNPR $1.37
- DOMH $1.50
- 52 Week High
- MNPR $8.65
- DOMH $3.20
- Technical
- Relative Strength Index (RSI)
- MNPR 61.76
- DOMH 51.91
- Support Level
- MNPR $5.06
- DOMH $1.80
- Resistance Level
- MNPR $5.73
- DOMH $1.98
- Average True Range (ATR)
- MNPR 0.60
- DOMH 0.10
- MACD
- MNPR -0.05
- DOMH -0.00
- Stochastic Oscillator
- MNPR 44.74
- DOMH 40.00
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.